Your browser doesn't support javascript.
loading
Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia.
Wei, Hui; Wang, Ying; Gale, Robert Peter; Lin, Dong; Zhou, Chunlin; Liu, Bingcheng; Qiu, Shaowei; Gu, Runxia; Li, Yan; Zhao, Xingli; Wei, Shuning; Gong, Benfa; Liu, Kaiqi; Gong, Xiaoyuan; Liu, Yuntao; Zhang, Guangji; Song, Zhen; Wang, Yang; Li, Wei; Mi, Yingchang; Wang, Jianxiang.
Afiliación
  • Wei H; State Key Laboratory of Experimental Hematology, Tianjin, China.
  • Wang Y; National Clinical Research Center for Blood Disease, Tianjin, China.
  • Gale RP; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Lin D; National Clinical Research Center for Blood Disease, Tianjin, China.
  • Zhou C; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Liu B; Division of Experimental Medicine, Department of Medicine, Hematology Research Center, Imperial College London, London, United Kingdom.
  • Qiu S; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Gu R; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Li Y; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Zhao X; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Wei S; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Gong B; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Liu K; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Gong X; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Liu Y; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Zhang G; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Song Z; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Wang Y; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Li W; Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Mi Y; National Clinical Research Center for Blood Disease, Tianjin, China.
  • Wang J; State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China.
Clin Cancer Res ; 26(13): 3154-3161, 2020 07 01.
Article en En | MEDLINE | ID: mdl-32029439
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Citarabina Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Citarabina Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos